Author/Authors :
Akbarian, Mahmood Department of Rheumatology - Shariati Hospital - School of Medicine - Tehran University of Medical Sciences , Gharibdoost, Farhad Department of Rheumatology - Shariati Hospital - School of Medicine - Tehran University of Medical Sciences , Hadjaliloo, Mehrzad Department of Rheumatology - Shariati Hospital - School of Medicine - Tehran University of Medical Sciences , Nadji, Abdolhadi Department of Rheumatology - Shariati Hospital - School of Medicine - Tehran University of Medical Sciences , Jamshidi, Ahmad Reza Department of Rheumatology - Shariati Hospital - School of Medicine - Tehran University of Medical Sciences , Shahram, Farhad Department of Rheumatology - Shariati Hospital - School of Medicine - Tehran University of Medical Sciences , Akhlaghi, Masoomeh Department of Rheumatology - Shariati Hospital - School of Medicine - Tehran University of Medical Sciences , Khosravi, Shahrzad Department of Rheumatology - Shariati Hospital - School of Medicine - Tehran University of Medical Sciences , Almasi, Simin Department of Rheumatology - Shariati Hospital - School of Medicine - Tehran University of Medical Sciences , Davatchi, Fereydoun Department of Rheumatology - Shariati Hospital - School of Medicine - Tehran University of Medical Sciences
Abstract :
At present, some clinical presentations and serological parameters such as products of
complement activation and elevation of autoantibodies (e.g. dsDNA antibodies), erythrocyte sedimentation
rate (ESR), levels of C-reactive protein (CRP), or cytokines such as IL-2/IL-2 receptor,
IL-6 and IL-10 are used as indirect serological markers with variable degrees of significance. To
date, no specific serological parameter is available to assess disease activity in SLE. Soluble serum
thrombomodulin is a new marker of endothelial cell injury and vasculitis. The objective of this
study was to determine in vivo soluble thrombomodulin as a marker of disease activity in SLE patients
and compare serum thrombomodulin in SEL patients with and without renal involvement
and inactive SLE patients. Sixty-four patients fulfilling ACR criteria with proven SLE with different
disease activities were tested for serum levels of Thrombomodulin and dsDNA by ELISA. C3,
C4 and FANA were also measured by standard laboratory tests. The clinical disease activity was
evaluated by the Systemic Lupus Erythematosus Activity Index (SLEDAI). Elevated soluble
thrombomodulin had significant correlations with an increased ANA level (P= 0.037), decrease
level of C3 (P =0.017), increase of SLEDAI (P=0.003) and strongly associated with renal involvement
in SLE. Thrombomodulin level and Anti dsDNA in active patients with and without renal
disease were higher than inactive patients. In SLE, serum thrombomodulin seems to be important
marker for evaluation of disease activity.
